Clarithromycin

Generic Name: Clarithromycin

Brand Names: Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₆₉NO_₁₃

CAS Number: 81103-11-9

Unique Ingredient Identifier: H1250JIK0A

Background: Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...

Indication: An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...

Associated Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections

Associated Therapies: -

Clinical Trials

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients

Not Applicable

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 91

Registration Number: NCT00001023

Locations: 🇺🇸
Univ of Maryland at Baltimore / Veterans Adm, Baltimore, Maryland, United States
🇺🇸
Denver Public Health Dept, Denver, Colorado, United States
🇺🇸
Med College of Virginia / School of Pharmacy, Richmond, Virginia, United States

and more 8 locations

The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

Not Applicable

Completed

Conditions: HIV Infections
Mycobacterium Avium-intracellular Infection

First Posted Date: 2001-08-31

Last Posted Date: 2015-01-16

Lead Sponsor: Abbott

Registration Number: NCT00002336

Locations: 🇺🇸
Dr Nelson Zide, Hollywood, Florida, United States
🇺🇸
Houston Veterans Administration Med Ctr, Houston, Texas, United States
🇺🇸
Univ of Arizona / Health Science Ctr, Tucson, Arizona, United States

and more 19 locations

An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT00002194

Locations: 🇺🇸
South Florida Bioavailability Clinic, Miami, Florida, United States

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

Phase 1

Completed

Conditions: Bacterial Infections
Mycoses
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00000826

Locations: 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

Phase 3

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT00001047

Locations: 🇺🇸
Henry Ford Hosp, Detroit, Michigan, United States
🇺🇸
Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States
🇺🇸
Richmond AIDS Consortium, Richmond, Virginia, United States

and more 13 locations

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

Phase 2

Completed

Conditions: HIV Infections
Mycobacterium Avium-intracellulare Infection

First Posted Date: 2001-08-31

Last Posted Date: 2011-02-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000644

Locations: 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

Phase 3

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1100

Registration Number: NCT00001030

Locations: 🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 39 locations

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Phase 2

Completed

Conditions: HIV Infections
Toxoplasmosis, Cerebral

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000794

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 13 locations

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

Phase 1

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-04

Lead Sponsor: Abbott

Target Recruit Count: 24

Registration Number: NCT00000971

Locations: 🇺🇸
Children's Hosp of Los Angeles, Los Angeles, California, United States
🇺🇸
Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States

Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease

Phase 2

Completed

Conditions: Mycobacterium Avium-intracellulare Infection

First Posted Date: 2000-02-25

Last Posted Date: 2015-03-25

Lead Sponsor: National Jewish Health

Target Recruit Count: 50

Registration Number: NCT00004689

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy